Literature DB >> 27252260

Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care.

M Y Choi1, M R W Barber1, C E H Barber1, A E Clarke1, M J Fritzler2.   

Abstract

Although challenging, developing evidence-based approaches to an early and accurate diagnosis of systemic lupus erythematosus is a key approach to preventing disease and lupus-associated morbidity and mortality. Advances in our understanding of preclinical and incomplete lupus erythematosus have enabled the identification of risk factors that may predict disease and the development of potential strategies aimed at primary prevention. Emerging data support the notion that there is a temporal disease progression from initial asymptomatic autoimmunity (preclinical lupus) through early clinical features of the disease (incomplete lupus erythematosus) to finally becoming fully classifiable systemic lupus erythematosus (complete lupus erythematosus). Here, we review the demographic, clinical, biomarker as well as genetic and environmental features that are reported to increase the risk of disease progression. Based on these risk factors, we propose a clinical care pathway for patients with early disease. We envisage that such a pathway, through early identification of disease, may improve patient outcomes, while reducing health care costs.
© The Author(s) 2016.

Entities:  

Keywords:  Systemic lupus erythematosus; biomarkers; care pathway; morbidity prevention

Mesh:

Substances:

Year:  2016        PMID: 27252260     DOI: 10.1177/0961203316640367

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Analysis of autoantibody profiles in two asbestiform fiber exposure cohorts.

Authors:  Jean C Pfau; Christopher Barbour; Brad Black; Kinta M Serve; Marvin J Fritzler
Journal:  J Toxicol Environ Health A       Date:  2018-09-19

Review 2.  Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.

Authors:  Vaishali R Moulton; Abel Suarez-Fueyo; Esra Meidan; Hao Li; Masayuki Mizui; George C Tsokos
Journal:  Trends Mol Med       Date:  2017-06-13       Impact factor: 11.951

Review 3.  Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development.

Authors:  May Y Choi; Karen H Costenbader
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 4.  The Role of Autoantibody Testing in Modern Personalized Medicine.

Authors:  Cristiane Kayser; Lívia Almeida Dutra; Edgard Torres Dos Reis-Neto; Charlles Heldan de Moura Castro; Marvin J Fritzler; Luis Eduardo C Andrade
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-04       Impact factor: 10.817

5.  Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Authors:  May Y Choi; Ann E Clarke; Yvan St Pierre; John G Hanly; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; Mary A Dooley; Paul R Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Susan Manzi; Ola Nived; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Thomas Stoll; Jill Buyon; Michael Mahler; Marvin J Fritzler
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06-12       Impact factor: 4.794

6.  Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment.

Authors:  Nancy J Olsen; Carl McAloose; Jamie Carter; Bobby Kwanghoon Han; Indu Raman; Quan-Zhen Li; Duanping Liao
Journal:  Autoimmune Dis       Date:  2016-12-28

Review 7.  Emerging technologies in autoantibody testing for rheumatic diseases.

Authors:  Nancy J Olsen; May Y Choi; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2017-07-24       Impact factor: 5.156

Review 8.  Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations.

Authors:  Sean Gavan; Ian Bruce; Katherine Payne
Journal:  Lupus Sci Med       Date:  2020-07

9.  The Utilization of Autoantibodies in Approaches to Precision Health.

Authors:  Marvin J Fritzler; Laura Martinez-Prat; May Y Choi; Michael Mahler
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.